TKNO
$2.88
Alpha Teknova, Inc.
Recent News
Alpha Teknova Q4 Earnings Call Highlights
Alpha Teknova (NASDAQ:TKNO) executives told investors the company delivered faster growth and improved profitability metrics in 2025, and said they believe the business is approaching an “inflection point” as it scales its mix of research-grade and GMP-grade reagents. On the company’s fourth-quarter
Alpha Teknova, Inc. Q4 2025 Earnings Call Summary
Moby summary of Alpha Teknova, Inc.'s Q4 2025 earnings call
Alpha Teknova Inc (TKNO) Q4 2025 Earnings Call Highlights: Navigating Growth Amid Challenges
Alpha Teknova Inc (TKNO) reports a 7% revenue growth and increased customer base, but faces hurdles with decreased average revenue per customer and a net loss for 2025.
Alpha Teknova: Q4 Earnings Snapshot
The Hollister, California-based company said it had a loss of 9 cents per share. The maker of reagents used by the biopharmaceutical industry posted revenue of $10 million in the period. For the year, the company reported a loss of $17.3 million, or 32 cents per share.
Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -1.63% and +356.43%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?